1. Field of the Invention
The present disclosure generally relates to devices that are used in nerve stimulation. More particularly, the present disclosure relates to an overwrap for wrapping nerve stimulation electrodes, such as are used in vagus nerve stimulation.
2. Description of the Related Art
Since its introduction, nerve stimulation has been used to treat a variety of neurological conditions. Vagus Nerve Stimulation (VNS) is one type of nerve stimulation that has been used as a treatment for intractable epilepsy. Typically, this involves stimulating the left cervical vagus nerve via an implanted electrode (the vagus nerve can also be stimulated outside of the cervical area and on the right vagus). VNS has been available for clinical treatment of epilepsy in the U.S. since 1997. The therapy is achieved through an implanted pulse generator that delivers a bipolar, biphasic pulse. The implant procedure is very similar to the implantation of a pacemaker. The generator is implanted subcutaneously, typically in the upper left chest wall. An electric lead is connected between the pulse generator and the electrode using a subcutaneous tunneling tool to the vagus nerve, which lies in the carotid sheath.
Several types of nerve stimulation electrodes have been developed. These include the nerve cuff (a cylinder with an open side), which is placed around the nerve and sutured closed, and helical electrodes, which can be flexible and provide a “self-sizing” feature due to their shape. Nerve stimulation electrodes are often attached in groups. That is, two or three electrodes are attached along the nerve, and are connected to the pulse generation device via an electric lead or wire. One of the devices attached to the nerve can be an electrically inactive electrode-type device, which serves as a tether or anchor for the group of electrodes. The electric lead can be attached to this tether electrode first, thus preventing tension or stress on the lead from being transmitted to the electrically active electrodes.
Some VNS electrodes can be difficult and time consuming to attach to a nerve. Where a surgeon applies three electrode devices (two electrodes and one tether) to the nerve, each of the three elements may need to be laced around the nerve independently. Additionally, ingrowth of tissue around and between electrodes can affect their effectiveness and can significantly hinder surgical removal or other adjustment of electrodes after implantation.
It is also desirable for electrodes to provide effective nerve stimulation with minimum power consumption. However, some of the current that is applied to nerve stimulation electrodes passes into surrounding tissue, rather than being directed into the nerve.
It is believed that some nerve stimulation electrodes and electrode systems that are currently available fall short in these areas. The present disclosure is directed to overcoming, or at least reducing the effects, of one or more of the issues set forth above.
It has been recognized that it would be advantageous to develop a nerve stimulation system that is easy to install and helps reduce ingrowth of tissue around a group of electrodes
It has also been recognized that it would be advantageous to develop a nerve stimulation system that promotes maximal stimulation of nerve fibers in order to achieve a therapeutic effect.
It has also been recognized that it would be advantageous to develop a nerve stimulation system that improves the efficacy of treatment while also conserving pulse generator battery power.
In accordance with one embodiment thereof, the present disclosure provides a nerve overwrap for an implantable nerve stimulation system that includes a flexible sheet of electrically insulative material, having an electrical resistivity of from about 108 ohm*m to about 1020 ohm*m, adapted to wrap substantially around a group of nerve stimulation electrodes.
In accordance with a more detailed embodiment, the sheet comprises silicone. In accordance with another more detailed embodiment, the sheet has a thickness of from about 0.005 inches to 0.05 inches.
In accordance with another more detailed embodiment, the sheet has a width sufficient to extend beyond opposing end electrodes of the group of electrodes when wrapped therearound.
In accordance with another more detailed embodiment, the group of electrodes comprises at least two electrically active electrodes, spaced a first distance from each other, and the sheet has a width that is at least 2.5 times the first distance. In accordance with another more detailed embodiment, the group of electrodes comprises at least two electrically active electrodes and one electrically inactive electrode, the active electrodes being spaced a first distance from each other, and the sheet has a width sufficient to extend beyond opposing end electrodes of the group of electrodes by a distance of about 0.2 inches to 1 inch when wrapped therearound.
In accordance with another more detailed embodiment, the sheet has opposing ends configured to be sutured together. In accordance with another more detailed embodiment, the sheet includes a flange, extending from one end of the sheet, configured for attachment to the opposing end when the sheet is wrapped around the group of electrodes on the nerve.
In accordance with another more detailed embodiment, the sheet is biased toward a substantially cylindrically wrapped configuration, defining a resilient encasement of flexible size. In accordance with another more detailed embodiment, the sheet includes first and second flanges, extending from opposite ends of the sheet, the flanges positioned to come into mating contact when the sheet is in the substantially cylindrically wrapped configuration.
In accordance with another more detailed embodiment, the sheet includes electrodes and an electrical lead attached to the electrodes, integrated into the overwrap sheet, the electrodes positioned on an inner surface of the sheet and having a substantially complete circular extent when the sheet is in the substantially cylindrically wrapped configuration.
In accordance with another more detailed embodiment, the sheet includes a mechanical interlocking device, adapted to mechanically connect opposing ends of the sheet together when wrapped around the electrodes. The mechanical interlocking device can be selected from the group consisting of: an elongate tab and slot mechanism, a plurality of protrusions and slots, and a strap and slot device.
In accordance with another more detailed embodiment, the sheet has a preformed shape defining a closeable pocket for surrounding the electrodes.
In accordance with another embodiment thereof, the present disclosure provides an implantable nerve stimulation system. The system includes a pulse generation device, suitable for subcutaneous implantation into a body; a group of electrodes, electrically connected to the pulse generation device, and configured for attachment along a nerve; and an overwrap, comprising a flexible sheet of electrically insulative material, having a resistivity of from about 108 ohm*m to about 1020 ohm*m, configured to wrap substantially completely around the group of electrodes.
In accordance with yet another embodiment thereof, the present disclosure provides a method for implanting a nerve stimulation system. The method includes the steps of attaching at least two stimulation electrodes along a common nerve, wrapping a single flexible sheet of insulative material, having an electrical resistivity of from about 108 ohm*m to about 1020 ohm*m, around the at least two electrodes, and attaching opposing ends of the sheet together so as to substantially completely encase the electrodes.
These and other embodiments of the present disclosure will be discussed more fully in the description. The features, functions, and advantages can be achieved independently in various embodiments of the claimed invention, or may be combined in yet other embodiments.
While the disclosure is susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and will be described in detail herein. However, it should be understood that the disclosure is not intended to be limited to the particular forms disclosed. Rather, the intention is to cover all modifications, equivalents and alternatives falling within the spirit and scope as defined by the appended claims.
Illustrative embodiments are described below as they might be employed in a nerve overwrap for nerve stimulation electrodes. In the interest of clarity, not all features of an actual implementation are described in this specification. It will of course be appreciated that in the development of any such actual embodiment, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which will vary from one implementation to another. Moreover, it will be appreciated that such a development effort might be complex and time-consuming, but would nevertheless be a routine undertaking for those of ordinary skill in the art having the benefit of this disclosure.
Further aspects and advantages of the various embodiments will become apparent from consideration of the following description and drawings. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is to be understood that modifications to the various disclosed embodiments may be made, and other embodiments may be utilized, without departing from the spirit and scope of the present invention. The following detailed description is, therefore, not to be taken in a limiting sense.
As used herein, the term “implantable” means a device that can be completely implanted into a human or animal body, with no portions of the apparatus extending outside the body after implantation.
As used herein, the terms “implantable device” and “implantable medical device” or “IMD” mean any type of electrical device that is implantable into a human or animal body, and is configured to monitor or affect a function of the body. Examples of implantable medical devices include cardiac pacemakers, nerve stimulation devices, and implantable drug delivery devices.
Shown in
A pictorial representation of a distal end section of a lead 30 in one embodiment of a nerve stimulation system is provided in
It is to be understood that the illustration of three helices attached to the nerve is only one of many possible embodiments of a nerve stimulation system. Various numbers of electrodes (e.g., three, four, five, or more) can be used to stimulate the nerve, if desired. Moreover, it is to be understood that the helical electrodes illustrated and described herein are only one type of electrode that can be used in conjunction with the overwrap system disclosed herein. Other types of electrodes, such as cuff-type electrodes, can also be used. In vagus nerve stimulation, the electrodes can be attached to the mid-cervical portion of the vagus nerve, inferior to the cardiac branches of the left vagus nerve. However, other attachment sites can also be used, such as the right vagus, near the cardiac plexus, or other nerves aside from the vagus large enough to wrap an electrode around.
Referring back to
The pulse generator 14 can be a multi-programmable device, which allows a physician to set various parameters of operation of the device. The programmable parameters can include signal amplitude (e.g., 0-3.5 mA), frequency (e.g., 1-30 Hz), pulse width (e.g., 130-1000 μs), signal ON time (e.g., 7-60 sec) and signal OFF time (e.g., 0.2-180 min). It is to be appreciated that these pulse parameters are only exemplary, and that other parameters can also be used. The pulses can be delivered at the specified amplitude and frequency over the course of the ON time, and then during the OFF time, no stimulation takes place. This type of device typically does not stimulate continuously because it has been found that the antiepileptic effect tends to last much longer than the actual time of stimulation. In one embodiment, pulse settings can be 2 mA, at 15 Hz frequency, 250 μs pulse width, with a 30 sec ON time, and 5 min OFF time. The variability in parameters allows the physician to adjust for greater efficacy or less severe side effects, depending on the patient. An implantable VNS system of this type and having these basic features is known to those of skill in the art, and is commercially available, such as from Cyberonics, Inc. of Houston, Tex.
As noted above, ease of implantation of VNS electrodes, tissue ingrowth and ease of removal, and current loss to surrounding tissue are among issues that are of concern with respect to VNS systems. Advantageously, as disclosed herein, apparatus and methods have been developed that address these concerns. Disclosed herein is a nerve overwrap for a VNS system that is relatively easy to implant, minimizes the positional variability of the electrodes, inhibits tissue ingrowth, and helps concentrate current that is injected into the nerve.
It has been determined that an insulative material, wrapped around a group of stimulation electrodes attached to a nerve, can significantly reduce current leakage into surrounding tissues, and increase current injection into the nerve. This is illustrated in
Shown in
The sheet has a length, measured along the front edge 112 in
In the embodiment of
The nerve overwrap sheet 102 can be biased toward a substantially cylindrically wrapped configuration. That is, the sheet can be formed to naturally rest in the curved “J” shape shown in
Shown in
The diameter of the wrap in its implanted configuration also affects current spread. It is desirable that the nerve overwrap be snug around the nerve, but not so tight as to constrict or put pressure on the nerve. In general, smaller diameters are believed to be most effective. However, if the wrap is too tight, there is a possibility of constricting the nerve. In general, it is believed that to provide a desired snugness, the inside diameter of the wrap can be from about 105% to about 200% of the outside diameter of the electrodes.
As shown in
In order to help reduce current spreading, it is believed to be desirable that the sheet has a width W that is at least sufficient to cover the active electrodes. In the embodiment of
Moreover, it is considered desirable that the sheet cover the active electrodes and also provide some amount of overhang D2 beyond them. Further, in order to help stabilize the entire group of electrodes and further reduce problems associated with tissue ingrowth, it is desirable that the sheet cover all of the electrode devices attached to the nerve, and provide some amount of overhang beyond the end of the exterior electrodes. The overhang D2 of the nerve overwrap can relate to its electrically insulative properties, which are desirable for reducing electrical losses and power usage in a nerve stimulation system, while still providing effective stimulation. It is believed that a suitable overhang D2 is in the range of 0.2 inches to 1 inch. In one embodiment, assuming electrodes having a spacing of 0.3 inches, a suitable overhang will be provided by a nerve overwrap having a total width W of 1.2 inches. In general, it is believed that a wider wrap is better at reducing current spread. Given the considerations presented above, an effective range could be between about ⅓ shorter than the total width presented above, and about 75% longer than that width.
As is well known, electrical insulation is essentially the same as electrical resistance, and is the opposite of conductance. Different materials provide different levels of resistance to electrical current, with some materials being good conductors and others being good resistors or insulators. In general, it is believed desirable that the nerve overwrap material have a resistivity in the range of from 108 ohm*m to 1020 ohm*m. Additionally, in order for the overwrap material to stay within the desired range of resistivity after implantation in the body, it is desirable that the overwrap material be non-porous, so that it will not soak up fluids or ion solutions, and not degrade within the body. Flexible silicone materials that are commercially available can provide electrical resistance in this range, and are also non-porous and resistant to degradation within the body. In addition to silicone, other insulative materials are available that have the desired durability for this application, and also have a resistance in the desired range (e.g., polytetrafluoroethylene (PTFE) or polyethersulfone).
As noted above, the thickness of the nerve overwrap sheet is primarily dependent upon mechanical and practical considerations, not electrical properties. It is believed that the thickness of the overwrap material does not significantly affect current spreading. Given the range of resistivities listed above, if a wrap were created thin enough to significantly affect the current spread, it is believed that it would probably not have the desired mechanical properties.
Current flowing in the nerve when provided with a nerve overwrap as disclosed herein has been modeled. Viewing
IZ=∫AJZ*dA [1]
In this equation, IZ is the total current flowing along the z axis of the nerve, and JZ is the current density vector in the z direction. IZ can be used as an indication of increased current flowing into the nerve. However, due to the directional dependence (i.e., the current flowing normal to the plane 200), it is not a direct measure of the total current flowing into the nerve, and an increase in IZ may indicate not only increased current into the nerve but also a change in the direction of the current flow. Using this computational model, it has been found that wrapping the electrodes with an insulative wrap should provide about a 3600% increase in axial current through the nerve. The total current flowing into the nerve is believed to increase by a lesser amount, but the increase in axial current flow is an indication that less current is lost to the surrounding tissues. This calculation from the computational model is relatively simple and straightforward to do, though it is believed by some that this quantity may not be applicable in-vivo or in bench trials. However, it is believed that the total current through the nerve could possibly be measured in a bench trial, such as by using a small, sensitive and accurate current probe, looped around a nerve or nerve stimulant between two stimulating electrodes.
The shape, size and configuration of the nerve overwrap can vary. Shown in
Another embodiment of a nerve overwrap 400 is shown in
Shown in
Another embodiment of a nerve overwrap is provided in
In this embodiment, electrodes 710 and the other components that make up the VNS lead are integrated into the central body portion of the self-wrapping nerve overwrap. The lead 712 is incorporated into the body portion 702 by over-molding or some other suitable manufacturing method. The self-wrapping overwrap provides a mechanism to hold the integrated lead electrodes 710 in direct contact with the vagus nerve.
The self-wrapping nerve overwrap 700 wraps the electrodes 710 completely around the nerve and simultaneously provides electrical insulation to reduce current leakage and promote current injection into the nerve. The orientation or shape of the electrodes 710 can vary. As shown in
The self-wrapping overwrap configuration shown in
By integrating the lead 710 into the self-wrapping overwrap, implantation time can be greatly reduced. It is believed that the time required to attach the nerve overwrap with integrated electrodes is comparable to the time otherwise required to attach a single helical electrode. Thus, time in the operating room and complexity of the device to be implanted are reduced. In addition, the lead assembly will have the clinical benefits of the nerve overwrap without the need for a second implanted device. Moreover, since the electrodes are integrated into the nerve overwrap, proper positioning of the electrodes with respect to the overwrap is ensured. This configuration also provides the other benefits of the nerve overwrap discussed herein, regarding current spread reduction, ease of explants, etc.
Although various embodiments have been shown and described, the invention is not so limited and will be understood to include all such modifications and variations as would be apparent to one skilled in the art. For example, equivalent elements may be substituted for those specifically shown and described, certain features may be used independently of other features, and the number and configuration of various vehicle components described above may be altered, all without departing from the spirit or scope of the invention as defined in the appended claims.
Such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed exemplary embodiments. It is to be understood that the phraseology of terminology employed herein is for the purpose of description and not of limitation. Accordingly, the foregoing description of the exemplary embodiments of the invention, as set forth above, are intended to be illustrative, not limiting. Various changes, modifications, and/or adaptations may be made without departing from the spirit and scope of this invention.
Number | Name | Date | Kind |
---|---|---|---|
4590946 | Loeb | May 1986 | A |
5324322 | Grill, Jr. et al. | Jun 1994 | A |
5433996 | Kranzler et al. | Jul 1995 | A |
5437900 | Kuzowski | Aug 1995 | A |
5462781 | Zukowski | Oct 1995 | A |
5487756 | Kallesoe et al. | Jan 1996 | A |
5505201 | Grill et al. | Apr 1996 | A |
5614284 | Kranzler et al. | Mar 1997 | A |
5833665 | Bootman et al. | Nov 1998 | A |
5899933 | Bhadra et al. | May 1999 | A |
5964702 | Grill, Jr. et al. | Oct 1999 | A |
5997895 | Narotam et al. | Dec 1999 | A |
6017366 | Berman | Jan 2000 | A |
6090996 | Li | Jul 2000 | A |
6596293 | Bootman et al. | Jul 2003 | B1 |
6600956 | Maschino et al. | Jul 2003 | B2 |
6620356 | Wong et al. | Sep 2003 | B1 |
6652594 | Francis et al. | Nov 2003 | B2 |
6689756 | Hesson et al. | Feb 2004 | B2 |
6716225 | Li et al. | Apr 2004 | B2 |
6780497 | Walter | Aug 2004 | B1 |
6810880 | Jennings, Jr. et al. | Nov 2004 | B1 |
6969523 | Mattern et al. | Nov 2005 | B1 |
6991637 | Crawley et al. | Jan 2006 | B2 |
7248930 | Woloszko et al. | Jul 2007 | B1 |
7561922 | Cohen et al. | Jul 2009 | B2 |
7596414 | Whitehurst et al. | Sep 2009 | B2 |
7672728 | Libbus et al. | Mar 2010 | B2 |
7805195 | Zealear | Sep 2010 | B2 |
7809442 | Bolea et al. | Oct 2010 | B2 |
7974706 | Moffitt et al. | Jul 2011 | B2 |
8116882 | Kowalczewski | Feb 2012 | B2 |
20080027524 | Maschino et al. | Jan 2008 | A1 |
20090210042 | Kowalczewski | Aug 2009 | A1 |
20100312320 | Faltys et al. | Dec 2010 | A1 |
Number | Date | Country |
---|---|---|
2009135140 | Nov 2009 | WO |
Entry |
---|
Material Properties of Silicone Rubber, Elastomers ; Polymers Data Sheets. www.matbase.com/materials/polymers/elastomers/siliconie-rubber/properties. |
International Application No. PCT/US2012/034147, International Search Report and Written Opinion dated Apr. 18, 2013, 18 pages. |
International Application No. PCT/US2012/034147, International Search Report and Written Opinion dated Dec. 11, 2012, 6 pages. |
U.S. Food and Drug Administration 510 (K) Summary for “Neurawrap”, Found at: http://www.accessdata.fda.gov/cdrh—docs/pdf4/k041620.pdf. |
U.S. Food and Drug Administration 510 (K) Summary for “Salutunnel”, Found at: http://www.accessdata.fda.gov/cdrh—docs/pdf10/k100382.pdf. |
U.S. Food and Drug Administration 510 (K) Summary for “Tendon Wrap”, Found at: http://www.accessdata.fda.gov/cdrh—docs/pdf5/k053655.pdf. |
U.S. Food and Drug Administration 510 (K) Summary for “SurgimeshXB”, Found at: http://www.accessdata.fda.gov/cdrh—docs/pdf7/k072974.pdf. |
U.S. Food and Drug Administration 510 (K) Summary for “Veritas Collagen Matrix”, Found at: http://www.accessdata.fda.gov/cdrh—docs/pdf8/k083039.pdf. |
U.S. Food and Drug Administration 510 (K) Summary for “Collagen Nerve Wrap”, Found at: http://www.accessdata.fda.gov/cdrh—docs/pdf6/k060952.pdf. |
Number | Date | Country | |
---|---|---|---|
20120277819 A1 | Nov 2012 | US |